Company Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases.
Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in phase 3 trial for the treatment of immunoglobulin A nephropathy.
It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections which is completed phase 2 clinical trial; and VT-109, a fusion protein targets B-cell activating factor and A proliferation-inducing ligand that is in preclinical for the treatment of B cell mediated diseases.
The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020.
Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
| Country | United States |
| Founded | 2016 |
| IPO Date | May 14, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 112 |
| CEO | Marshall Fordyce |
Contact Details
Address: 2000 Sierra Point Parkway, Suite 1200 Brisbane, California 94005 United States | |
| Phone | 650 770 0077 |
| Website | veratx.com |
Stock Details
| Ticker Symbol | VERA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 0001831828 |
| CUSIP Number | 92337R101 |
| ISIN Number | US92337R1014 |
| Employer ID | 81-2744449 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Marshall W. Fordyce M.D. | Founder, President, Chief Executive Officer and Director |
| Sean P. Grant M.B.A. | Chief Financial Officer |
| David L. Johnson M.B.A. | Chief Opearating Officer |
| Joseph R. Young M.B.A. | Senior Vice President of Finance and Chief Accounting Officer |
| Dr. Allen Ebens B.Sc., Ph.D. | Executive Vice President of Research |
| Jason S Carter | Chief Legal Officer |
| Kelly Rauber | Senior Vice President of Human Resources |
| Tom Doan | Executive Vice President of Development Operations |
| Lauren Frenz M.B.A. | Chief Business Officer |
| Julien E. Capers J.D. | Senior Vice President of Legal |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 28, 2025 | 10-K | Annual Report |
| Feb 26, 2025 | 144 | Filing |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 8, 2025 | 144 | Filing |
| Dec 18, 2024 | 144 | Filing |
| Dec 11, 2024 | 144 | Filing |
| Nov 25, 2024 | 144 | Filing |